Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8046247 | 0.89 | FDPS (0.84) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL8046251 | 0.89 | FDPS (0.84) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL28859349 | 0.89 | FDPS (0.84) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL28859350 | 0.89 | FDPS (0.84) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL31087309 | 0.89 | FDPS (0.84) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL10929433 | 0.89 | KDM4E (0.69) | FDPSNFE2L2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4254363 | 0.86 | FDPS (0.80) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL4254365 | 0.86 | FDPS (0.80) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL18699268 | 0.84 | FDPS (0.59) | FDPSMAOBNFE2L2APPKDM4E | |
| SCHEMBL30690419 | 0.84 | FDPS (0.72) | FDPSMAOBNFE2L2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150203-B1 | COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | ALLIANZ PHARMASCIENCE LTD (TW) | 2020-02-19 | — | — | EP | disclosed |
| US-20190212326-A1 | Method for the Selection of Patients and Kit | ALLIANZ PHARMASCIENCE LTD. (TW) | 2019-07-11 | — | — | US | disclosed |
| EP-3508855-A1 | METHOD FOR THE SELECTION OF PATIENTS AND KIT | Allianz Pharmascience Ltd (TW) | 2019-07-10 | — | — | EP | disclosed |
| EP-3150203-A1 | COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Allianz Pharmascience Ltd (TW) | 2017-04-05 | — | — | EP | disclosed |
| US-9562025-B2 | Compounds with (1E, 6E)-1,7-Bis-(3,4-dimethoxyphenyl)-4-4-distributed-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ALLIANZ PHARMASCIENCE LTD. (TW) | 2017-02-07 | — | — | US | disclosed |
| US-20160264539-A1 | COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Annji Pharmaceutical Co., Ltd. (TW) | 2016-09-15 | — | — | US | disclosed |
| EP-2993165-A2 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | Allianz Pharmascience Ltd (TW) | 2016-03-09 | — | — | EP | disclosed |
| EP-2104659-B1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | ANDROSCIENCE CORP (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2015-07-09 | — | — | US | disclosed |
| US-9000222-B2 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ANDROSCIENCE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130261121-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-03 | — | — | US | disclosed |
| US-8236852-B2 | Drugs/cosmetics having at least one (substituted phenyl)-propenal moiety; bioavailability' water solubility; antiandrogens; antiinflammatory and wound healing agents; antiarthritic agents; acne; alopecia, hirsutism; anticarcinogenic agents; cancer of the bladder, liver, breast; Kennedy's disease | ANDROSCIENCE CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236852-B2 | Drugs/cosmetics having at least one (substituted phenyl)-propenal moiety; bioavailability' water solubility; antiandrogens; antiinflammatory and wound healing agents; antiarthritic agents; acne; alopecia, hirsutism; anticarcinogenic agents; cancer of the bladder, liver, breast; Kennedy's disease | ANDROSCIENCE CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-8202905-B2 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | ANDROSCIENCE CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202905-B2 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | ANDROSCIENCE CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2010-11-18 | — | — | US | disclosed |
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2010-11-18 | — | — | US | disclosed |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2008-08-07 | — | — | US | disclosed |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2008-08-07 | — | — | US | disclosed |
| WO-2008085984-A1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | ANDROSCIENCE CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | AR, CYP17A1, CYP19A1 | FDPS 129/4885MAOB 1026/4885NFE2L2 73/4885 |
| US-20190212326-A1 | Method for the Selection of Patients and Kit | MYC, AURKC, AR | FDPS 4267/4885MAOB 2172/4885NFE2L2 134/4885 |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | AR, CYP17A1, CYP19A1 | FDPS 129/4885MAOB 1026/4885NFE2L2 73/4885 |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | AR, BRCA1, CYP17A1 | FDPS 2320/4885MAOB 885/4885NFE2L2 308/4885 |
| US-20130261121-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | AR, BRCA1, CYP17A1 | FDPS 2320/4885MAOB 885/4885NFE2L2 308/4885 |
| US-20160264539-A1 | COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | AR, CYP17A1, SRD5A1 | FDPS 1245/4885MAOB 2164/4885NFE2L2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.